HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $7 price target for the company's stock.
November 15, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reaffirmed a Buy rating on Praxis Precision Medicine with a $7 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst like Douglas Tsao could lead to increased investor confidence in PRAX, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100